Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 23 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Desipramine can predict a clinical response in bowel disorders

Blood levels of Desipramine are associated with a clinical response in functional bowel disorders, however, with dosages up to 150 mg, there is no relationship between total dose or plasma level and the clinical response, reports the latest issue of American Journal of Gastroenterology

News image

fiogf49gjkf04

As shown in the per protocol analysis of a recent randomized, controlled trial, when tolerated, Desipramine is effective over placebo in treating moderate-to-severe functional bowel disorders.

Clinical experience suggests that the benefit from tricyclic antidepressants in functional bowel disorders can be achieved at doses lower than those used to treat major depression.

Within psychiatry, when using higher dosage of tricyclic antidepressants, plasma levels can be used to adjust daily dosage to optimize a treatment response.

However, in functional bowel disorders, it is not known whether plasma levels at the lower dosage are similarly related to a clinical response.

Dr Halpert and colleagues from Canada determined whether Desipramine blood levels or dose taken can predict a clinical response in treating functional bowel disorders.

The researchers included 431 patients with functional bowel disorder that were part of a study of 12 weeks of antidepressant and psychological treatment at the University of North Carolina and the University of Toronto.

There was a modest correlation between mean Desipramine dose and Desipramine blood level at week 6
American Journal of Gastroenterology

The research team studied those participants who completed treatment (per protocol analysis) taking Desipramine (N = 97, dose 50,150 mg/day) or pill placebo (N = 5,513 pills/day).

The primary outcome measure was defined by the investigators as a composite score (Satisfaction with Treatment, McGill Pain Questionnaire, Global Well-being, and Irritable Bowel Syndrome-Quality of Life).

The composite score was correlated with Desipramine plasma levels at week 6, and the number of pills taken over the duration of the 12 week treatment period.

In addition, the reasearchers also compared Desipramine dose with Desipramine plasma levels.

The team reported a modest correlation between mean Desipramine dose at weeks 5 and 6 and Desipramine blood level at week 6.

However, the research team noted no significant correlations between the composite score either with Desipramine dose or with Desipramine blood levels.

Dr Halpert concludes, “Detectible blood levels of Desipramine are associated with a clinical response in functional bowel disorders.”

“However, with dosages up to 150 mg, there is no relationship between total dose or plasma level and the clinical response."

American Journal of Gastroenterology 2005: 100(3): 664
14 March 2005

Go to top of page Email this page Email this page to a colleague

 23 November 2017 
Distance travelling for rectal cancer outcomes
 23 November 2017 
Incidence of biopsy-verified celiac disease
 23 November 2017 
Pharmacological management of GERD
 22 November 2017 
Surgical treatment delays influence survival in colon cancer
 22 November 2017 
Golimumab in Crohn's disease
 22 November 2017 
Challenges of US-trained gastroenterologists when abroad
 21 November 2017 
Prepregnancy obesity and maternal mortality
 21 November 2017 
Preoperative optimization in IBD patients
 21 November 2017 
Cholangiopathy in critically ill patients
 20 November 2017 
Socioeconomic characteristics in diverticular disease
 20 November 2017 
Barriers to hepatitis C treatment
 20 November 2017 
Endoscopic indices of disease activity for Crohn’s
 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 15 November 2017 
Medication nonadherence and health care costs
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Follow-up of positive results on fecal blood tests
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us